Bevacizumab proves to be a new treatment for nasopharyngeal carcinoma

Good news for the patients suffering from the advanced diseases of nasopharyngeal carcinoma. The results of the clinical trial say that Bevacizumab will be more effective in treating nasopharyngeal carcinoma. It may give the effective treatment by blocking the spread of the diseases to other parts of the body. The combination of the treatment in the clinical trial widely used anti-cancer drug bevacizumab with standard chemoradiation therapy helped to increase the survival period of the patients. 

After the treatment with the combination of bevacizumab, at 2 years, 91 percent of the patients were still alive when compared to the placebo treatment with the standard one. Bevacizumab treats nasopharyngeal carcinoma by blocking vascular endothelial growth factor related to poor prognosis in head and neck cancers that are expressed in two thirds of Nasopharyngeal carcinoma.